Skip to main navigation

Skip to Content

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Stock Information
Financials
- SEC Filings
Resources

News Releases

Year

Nov 09, 2026

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

Nov 04, 2026

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

Nov 03, 2026

Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference

Oct 23, 2026

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

Oct 16, 2026

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Sep 03, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 01, 2026

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Aug 11, 2026

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Aug 06, 2026

Tango Therapeutics Announces Executive Chair Transition

Jun 22, 2026

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 23

Print

RSS Feeds

Email Alerts

Contact IR

Tango Therapeutics, Inc
201 Brookline Avenue, Suite 901
Boston, Massachusetts 02215
Tel: +1-857-320-4900

contact | careers | Cookie Policy |